SI1583541T1 - Spojine in postopki za povečanje nevrogeneze - Google Patents

Spojine in postopki za povečanje nevrogeneze

Info

Publication number
SI1583541T1
SI1583541T1 SI200331983T SI200331983T SI1583541T1 SI 1583541 T1 SI1583541 T1 SI 1583541T1 SI 200331983 T SI200331983 T SI 200331983T SI 200331983 T SI200331983 T SI 200331983T SI 1583541 T1 SI1583541 T1 SI 1583541T1
Authority
SI
Slovenia
Prior art keywords
methods
agents
compounds
increasing neurogenesis
neurogenesis
Prior art date
Application number
SI200331983T
Other languages
English (en)
Inventor
Goran Bertilsson
Rikard Erlandsson
Jonas Frisen
Anders Haegerstrand
Jessica Heidrich
Kristina Hellstrom
Johan Haggblad
Katarina Jansson
Jarkko Kortesmaa
Per Lindquist
Hanna Framme
Jacqueline Mcguire
Alex Mercer
Karl Nyberg
Amina Ossoinak
Cesare Patrone
Harriet Ronnholm
Olof Zachrisson
Lilian Wikstrom
Original Assignee
Neuronova Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326612&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1583541(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuronova Ab filed Critical Neuronova Ab
Publication of SI1583541T1 publication Critical patent/SI1583541T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SI200331983T 2002-11-20 2003-11-20 Spojine in postopki za povečanje nevrogeneze SI1583541T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42791202P 2002-11-20 2002-11-20
EP03772495A EP1583541B1 (en) 2002-11-20 2003-11-20 Compounds and methods for increasing neurogenesis
PCT/IB2003/005311 WO2004045592A2 (en) 2002-11-20 2003-11-20 Compounds and methods for increasing neurogenesis

Publications (1)

Publication Number Publication Date
SI1583541T1 true SI1583541T1 (sl) 2011-08-31

Family

ID=32326612

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331983T SI1583541T1 (sl) 2002-11-20 2003-11-20 Spojine in postopki za povečanje nevrogeneze

Country Status (14)

Country Link
US (1) US20050009847A1 (sl)
EP (1) EP1583541B1 (sl)
JP (2) JP5420813B2 (sl)
AT (1) ATE494904T1 (sl)
AU (1) AU2003280117B2 (sl)
CA (1) CA2506850C (sl)
CY (1) CY1111386T1 (sl)
DE (1) DE60335743D1 (sl)
DK (1) DK1583541T3 (sl)
ES (1) ES2359720T3 (sl)
HK (1) HK1091112A1 (sl)
PT (1) PT1583541E (sl)
SI (1) SI1583541T1 (sl)
WO (1) WO2004045592A2 (sl)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691145B2 (en) * 1999-10-22 2010-04-06 Facet Solutions, Inc. Prostheses, systems and methods for replacement of natural facet joints with artificial facet joint surfaces
CA2458261A1 (en) * 2001-08-30 2003-03-06 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use thereof
AU2002325711C1 (en) 2001-09-14 2008-05-29 Stem Cell Therapeutics Inc. Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof
US20030054551A1 (en) * 2001-09-18 2003-03-20 Stem Cell Therapeutics Inc. Effect of growth hormone and IGF-1 on neural stem cells
WO2004011497A1 (en) * 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
FR2856595B1 (fr) * 2003-06-27 2008-05-30 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de deficits cognitifs.
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
EP1750752A2 (en) * 2003-11-20 2007-02-14 Neuronova AB Compounds and methods for increasing neurogenesis
ATE556716T1 (de) * 2004-02-13 2012-05-15 Stem Cell Therapeutics Corp Verwendung des luteinisierenden hormons (lh) und von choriongonadotrophin (hcg) für die proliferation von neuralen stammzellen und neurogenese
WO2005116065A1 (en) 2004-05-24 2005-12-08 Institut De Cardiologie De Montréal Labelled adrenomedullin derivatives and their use for imaging and therapy
US8475764B2 (en) 2004-05-24 2013-07-02 Institut De Cardiologie De Montreal Labelled adrenomedullin derivatives and their use for imaging and therapy
EP1619251A1 (en) 2004-07-22 2006-01-25 Prosensa B.V. A mRNA splice variant of the doublecortin-like kinase gene and its use in cancer diagnosis and therapy
EP1850840A2 (en) * 2005-01-13 2007-11-07 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
US20090220587A1 (en) * 2005-02-01 2009-09-03 United State Army Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands
US7741431B2 (en) * 2005-02-01 2010-06-22 The United States Of America As Represented By The Secretary Of The Army Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof
DE102005036094A1 (de) * 2005-08-01 2007-02-08 B.R.A.H.M.S Ag In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1928488A4 (en) * 2005-09-27 2009-07-22 Stem Cell Therapeutics Corp REGULATION OF OLIGODENDROCYTE PRECURSOR CELL PROLIFERATION WITH PROLACTIN
JP2009512711A (ja) * 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
JP5050195B2 (ja) * 2006-02-14 2012-10-17 国立大学法人 岡山大学 神経細胞分化誘導剤
JP5424291B2 (ja) * 2006-03-03 2014-02-26 独立行政法人国立循環器病研究センター 骨髄細胞の動員剤および動員方法
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007223036A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009149524A (ja) * 2006-03-16 2009-07-09 Kyushu Univ アルツハイマー病の予防・治療剤
JP2009530234A (ja) * 2006-03-17 2009-08-27 ステム セル セラピューティクス コーポレイション 神経変性疾患の治療のためのｌｈまたはｈｃｇ、およびｅｐｏについての投与レジメン
US20090197823A1 (en) 2006-05-09 2009-08-06 Braincells, Inc. Aliskiren modulation of neurogenesis
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
KR100838013B1 (ko) * 2006-06-07 2008-06-12 제일약품주식회사 인간배아줄기세포로부터 단계적 선별법을 통해 고수율로신경전구세포, 신경세포 및 기능성 도파민신경세포를생성하는 방법
US7998971B2 (en) * 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100129319A1 (en) * 2006-12-14 2010-05-27 Per Lindquist Treatment of disease or injury of the nervous system using agents that decrease the activity of the melanocortin 4 receptor
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
CA2675132A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
US20080188457A1 (en) * 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
WO2008138141A1 (en) * 2007-05-11 2008-11-20 Institut De Cardiologie De Montréal Labelled adrenomedullin derivatives and their use for imaging and therapy.
AU2008282931A1 (en) * 2007-07-27 2009-02-05 Immuneregen Biosciences, Inc. Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance P or an analog thereof
RU2010114030A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение пептида в качестве терапевтического средства
JP2010538988A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのミニガストリン
WO2009033809A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
AU2008306255A1 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of neurotrophic factor for retinal cholinergic neruons (NFRCN) and chorionic gonadotropin-beta (109-145) as therapeutic agents
CA2715110A1 (fr) * 2008-01-18 2009-09-17 Centre National De La Recherche Scientifique (Cnrs) Composes utilisables pour le traitement de douleurs neuropathiques
FR2926464B1 (fr) * 2008-01-18 2012-01-20 Centre Nat Rech Scient Composes utilisables pour le traitement de douleurs neuropathiques
WO2009123877A1 (en) * 2008-03-21 2009-10-08 Braincells, Inc. A method of treating a nervous system disorder by modulation of neurogenesis with mcc-257
JPWO2009136587A1 (ja) * 2008-05-08 2011-09-08 株式会社カネカ 抗疲労組成物
WO2010019450A2 (en) * 2008-08-09 2010-02-18 Nyles Bauer Synergizing active compounds for treating inflammation and other conditions
GB0815315D0 (en) * 2008-08-21 2008-09-24 Univ Leiden Organ protection
KR101939557B1 (ko) 2008-10-17 2019-01-17 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AU2010224486B2 (en) 2009-03-20 2014-04-24 Hg&H Pharmaceuticals (Pty) Ltd Sceletium extract and uses thereof
EP2408446B1 (en) 2009-03-20 2019-09-11 HG&H Pharmaceuticals (Pty) Limited Use of pharmaceutical compositions containing mesembrenone
US20120083447A1 (en) 2009-04-30 2012-04-05 Midwestern University Novel Therapeutic Treatments Using Centhaquin
SG176000A1 (en) * 2009-05-13 2011-12-29 Protein Delivery Solutions Llc Pharmaceutical system for trans-membrane delivery
RU2537239C2 (ru) 2009-11-13 2014-12-27 Санофи-Авентис Дойчланд Гмбх Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин
AU2010317994B2 (en) 2009-11-13 2014-03-06 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
ES2688072T3 (es) * 2010-05-11 2018-10-30 Mallinckrodt Ard Ip Limited ACTH para el tratamiento de la esclerosis lateral amiotrófica
SG10201503032UA (en) * 2010-06-16 2015-06-29 Sigma Tau Ind Farmaceuti Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
ES2575684T3 (es) 2010-08-31 2016-06-30 Bionure Farma, S.L. Agonistas de receptores de neurotrofinas y su uso como medicamentos
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US20140221319A1 (en) * 2011-06-29 2014-08-07 Mayo Foundation For Medical Education And Research Small Molecule CD38 Inhibitors and Methods of Using Same
CA2847247C (en) 2011-08-29 2019-10-15 Sanford-Burnham Medical Research Institute Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366691A1 (en) 2012-12-21 2015-07-09 Sanofi Exendin-4 derivatives
PL3019242T3 (pl) 2013-07-08 2021-02-08 Midwestern University Kompozycje i sposoby leczenia zaburzeń neuropsychiatrycznych przy zastosowaniu agonisty receptora endoteliny-B
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
NZ733670A (en) 2014-12-12 2021-12-24 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
JP6820868B2 (ja) * 2015-06-22 2021-01-27 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 動物において神経新生を増強するための組成物及び方法
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
WO2017170180A1 (ja) * 2016-03-31 2017-10-05 味の素株式会社 神経分化能を亢進させる神経幹細胞用培地
WO2018074463A1 (ja) * 2016-10-17 2018-04-26 国立大学法人 熊本大学 ｃＡＭＰの増加をメカニズムとする有機酸血症における神経障害治療薬剤
KR102026156B1 (ko) * 2018-03-16 2019-09-27 (주)메디노 신경줄기세포의 신경분화 방법
AU2019288490A1 (en) 2018-06-21 2020-12-03 Nevada Research & Innovation Corporation Disease modifying methods for treating neurodegenerative diseases using nootropic agents
WO2021011878A1 (en) * 2019-07-18 2021-01-21 Venturis Therapeutics, Inc. Method of treating parkinson's disease
JP2022104448A (ja) * 2020-12-28 2022-07-08 純一 今村 認知症治療薬
CN113121641B (zh) * 2021-03-11 2022-11-01 武汉英纳氏药业有限公司 一类多功能多肽及其在医药领域的应用
CN115869459A (zh) * 2021-09-27 2023-03-31 广州图微科创生物科技有限公司 促伤口愈合的多肽水凝胶及其制备方法与应用
CN115887619B (zh) * 2021-09-30 2024-03-26 四川大学 中脑星形胶质细胞源性神经营养因子的用途及药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680996B2 (en) * 1993-12-17 1997-08-14 Novavax, Inc. Method of transmitting a biologically active material to a cell
US5968829A (en) * 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6268352B1 (en) * 1998-09-02 2001-07-31 The Regents Of The University Of California Promoters of neural regeneration
US6284539B1 (en) * 1998-10-09 2001-09-04 Neuralstem Biopharmaceuticals, Ltd. Method for generating dopaminergic cells derived from neural precursors
US6610540B1 (en) * 1998-11-18 2003-08-26 California Institute Of Technology Low oxygen culturing of central nervous system progenitor cells
US7741310B2 (en) * 2000-05-05 2010-06-22 Research Foundation Of The City University Of New York Methods for stimulating nervous system regeneration and repair by regulating arginase I and polyamine synthesis
WO2002083877A1 (en) * 2001-04-11 2002-10-24 Stem Cell Therapeutics Inc. Production of tyrosine hydroxylase positive neurons
US20040247571A1 (en) * 2001-04-23 2004-12-09 Xia Meijer Neural cells expressing tyrosine hydroxylase

Also Published As

Publication number Publication date
AU2003280117A1 (en) 2004-06-15
ES2359720T3 (es) 2011-05-26
US20050009847A1 (en) 2005-01-13
CY1111386T1 (el) 2015-08-05
DK1583541T3 (da) 2011-04-11
CA2506850A1 (en) 2004-06-03
JP5420813B2 (ja) 2014-02-19
JP2010195841A (ja) 2010-09-09
WO2004045592A3 (en) 2004-11-04
DE60335743D1 (de) 2011-02-24
JP2006514630A (ja) 2006-05-11
WO2004045592A2 (en) 2004-06-03
CA2506850C (en) 2014-05-13
PT1583541E (pt) 2011-04-06
AU2003280117B2 (en) 2009-09-10
ATE494904T1 (de) 2011-01-15
EP1583541A2 (en) 2005-10-12
EP1583541B1 (en) 2011-01-12
JP5421194B2 (ja) 2014-02-19
HK1091112A1 (en) 2007-01-12

Similar Documents

Publication Publication Date Title
HK1091112A1 (en) Compounds and methods for increasing neurogenesis
MXPA05005107A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
HK1080467B (zh) 用於治療過度增生疾病的苯並呋喃和苯並噻吩衍生物
GB0223040D0 (en) Therapeutic compounds
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
GB0223038D0 (en) Therapeutic compounds
GB0225474D0 (en) Therapeutic agents
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
EA200401345A1 (ru) Лечение гастропареза
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
EP1578760A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS
GB0326633D0 (en) Therapeutic agents
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
SI1532131T1 (sl) Motilidne spojine
MXPA05011233A (es) Vectores peptidicos.
GB0207653D0 (en) Methods of using lamellar bodies for therapeutic purposes
TR200200278T2 (tr) Kalsilitik bileşimler
EP1436279A4 (en) CHEMICAL COMPOUNDS
CY1111319T1 (el) Ενωση 4-μεθυλεξανοϊκης κααλαλιδης f
MXPA04004757A (es) Uso de una ascomicina para el tratamiento de blefaritis.